For research use only. Not for therapeutic Use.
INO-1001(CAT: I006838) is a small molecule inhibitor of poly (ADP-ribose) polymerase (PARP) enzyme. PARP is involved in DNA damage repair and maintenance of genomic stability. By inhibiting PARP, INO-1001 can enhance the effectiveness of certain cancer treatments, such as chemotherapy and radiation therapy. In addition to its potential use in cancer treatment, INO-1001 has also been studied as a potential treatment for other conditions, such as myocardial infarction and ischemia-reperfusion injury. Clinical studies have shown that INO-1001 is generally well-tolerated, with mild to moderate side effects.
| Catalog Number | I006838 |
| CAS Number | 501364-82-5 (free base) |
| Synonyms | IN01001; INO-1001; INO 1001;N-(3-morpholinopropyl)-5-oxo-6,11-dihydro-5H-indeno[1,2-c]isoquinoline-9-sulfonamide |
| Molecular Formula | C23H25N3O4S |
| Purity | ≥95% |
| Target | Epigenetics |
| Solubility | Soluble in DMSO, not in water |
| Storage | 0 - 4°C for short term or -20 °C for long term |
| IUPAC Name | N-(3-morpholin-4-ylpropyl)-5-oxo-6,11-dihydroindeno[1,2-c]isoquinoline-9-sulfonamide |
| InChI | InChI=1S/C23H25N3O4S/c27-23-20-5-2-1-4-19(20)21-15-16-14-17(6-7-18(16)22(21)25-23)31(28,29)24-8-3-9-26-10-12-30-13-11-26/h1-2,4-7,14,24H,3,8-13,15H2,(H,25,27) |
| InChIKey | LTZVLHHIAUKGBP-UHFFFAOYSA-N |
| SMILES | C1COCCN1CCCNS(=O)(=O)C2=CC3=C(C=C2)C4=C(C3)C5=CC=CC=C5C(=O)N4 |
| Reference | </br>1:Therapeutic injection of PARP inhibitor INO-1001 preserves cardiac function in porcine myocardial ischemia and reperfusion without reducing infarct size. Roesner JP, Mersmann J, Bergt S, Bohnenberg K, Barthuber C, Szabo C, Nöldge-Schomburg GE, Zacharowski K.Shock. 2010 May;33(5):507-12. doi: 10.1097/SHK.0b013e3181c4fb08. PMID: 20395771 </br>2:A phase IB trial of intravenous INO-1001 plus oral temozolomide in subjects with unresectable stage-III or IV melanoma. Bedikian AY, Papadopoulos NE, Kim KB, Hwu WJ, Homsi J, Glass MR, Cain S, Rudewicz P, Vernillet L, Hwu P.Cancer Invest. 2009 Aug;27(7):756-63. doi: 10.1080/07357900802709159. PMID: 19440934 </br>3:A randomized, placebo-controlled trial to evaluate the tolerability, safety, pharmacokinetics, and pharmacodynamics of a potent inhibitor of poly(ADP-ribose) polymerase (INO-1001) in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of the TIMI 37 trial. Morrow DA, Brickman CM, Murphy SA, Baran K, Krakover R, Dauerman H, Kumar S, Slomowitz N, Grip L, McCabe CH, Salzman AL.J Thromb Thrombolysis. 2009 May;27(4):359-64. doi: 10.1007/s11239-008-0230-1. Epub 2008 Jun 6. PMID: 18535785 </br>4:Local administration of the poly(ADP-ribose) polymerase inhibitor INO-1001 prevents NAD+ depletion and improves water maze performance after traumatic brain injury in mice. Clark RS, Vagni VA, Nathaniel PD, Jenkins LW, Dixon CE, Szabó C.J Neurotrauma. 2007 Aug;24(8):1399-405. PMID: 17711401 </br>5:INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase, enhances tumor response to doxorubicin. Mason KA, Valdecanas D, Hunter NR, Milas L.Invest New Drugs. 2008 Feb;26(1):1-5. Epub 2007 Jul 13. PMID: 17628743 </br>6:Single dose treatment with PARP-inhibitor INO-1001 improves aging-associated cardiac and vascular dysfunction. Radovits T, Seres L, Gero D, Berger I, Szabó C, Karck M, Szabó G.Exp Gerontol. 2007 Jul;42(7):676-85. Epub 2007 Feb 20. PMID: 17383839 Free PMC Article</br>7:The parp-1 inhibitor ino-1001 facilitates hemodynamic stabilization without affecting DNA repair in porcine thoracic aortic cross-clamping-induced ischemia/reperfusion. Hauser B, Gröger M, Ehrmann U, Albicini M, Brückner UB, Schelzig H, Venkatesh B, Li H, Szabó C, Speit G, Radermacher P, Kick J.Shock. 2006 Jun;25(6):633-40. PMID: 16721272 </br>8:In vitro effect of the potent poly(ADP-ribose) polymerase (PARP) inhibitor INO-1001 alone and in combination with aspirin, eptifibatide, tirofiban, enoxaparin or alteplase on haemostatic parameters. Tóth O, Szabó C, Kecskés M, Pótó L, Nagy A, Losonczy H.Life Sci. 2006 Jun 20;79(4):317-23. Epub 2006 Feb 9. PMID: 16480745 </br>9:Beneficial effects of PJ34 and INO-1001, two novel water-soluble poly(ADP-ribose) polymerase inhibitors, on the consequences of traumatic brain injury in rat. Besson VC, Zsengellér Z, Plotkine M, Szabó C, Marchand-Verrecchia C.Brain Res. 2005 Apr 18;1041(2):149-56. PMID: 15829224 </br>10:INO-1001 a novel poly(ADP-ribose) polymerase (PARP) inhibitor improves cardiac and pulmonary function after crystalloid cardioplegia and extracorporal circulation. Szabó G, Soós P, Mandera S, Heger U, Flechtenmacher C, Bährle S, Seres L, Cziráki A, Gries A, Zsengellér Z, Vahl CF, Hagl S, Szabó C.Shock. 2004 May;21(5):426-32. PMID: 15087818 |
